Does additional HIPEC help after CRS in peritoneal disseminated gastric cancer?
References
- 1. Ferlay J, Shin HR, Bray F, et al.: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
- 2. Ferlay J, Soerjomataram I, Dikshit R, et al.: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-E386.
- 3. Ajani JA, Bentrem DJ, Besh S, et al.: Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013;11:531-46.
- 4. Okines A, Verheij M, Allum W, et al.: Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v50-4. doi: 10.1093/annonc/mdq164.:v50-v54.
10.1093/annonc/mdq164.:v50-v54 - 5. Chang JS, Kim KH, Keum KC, et al.: Recursive partition analysis of peritoneal and systemic recurrence in patients with gastric cancer who underwent D2 gastrectomy: Implications for neoadjuvant therapy consideration. J Surg Oncol. 2016;114:859-64.
- 6. Seyfried F, von Rahden BH, Miras AD, et al.: Incidence, time course and independent risk factors for metachronous peritoneal carcinomatosis of gastric origin--a longitudinal experience from a prospectively collected database of 1108 patients. BMC Cancer 2015;15:73. doi: 10.1186/s12885-015-1081-8.:73-1081, 2015
10.1186/s12885-015-1081-8.:73-10812015 - 7. Yonemura Y, Endou Y, Sasaki T, et al.: Surgical treatment for peritoneal carcinomatosis from gastric cancer. Eur J Surg Oncol. 2010;36:1131-8.
- 8. Roviello F, Caruso S, Neri A, et al.: Treatment and prevention of peritoneal carcinomatosis from gastric cancer by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: overview and rationale. Eur J Surg Oncol. 2013;39:1309-16.
- 9. Yan TD, Black D, Sugarbaker PH, et al.: A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol. 2007;14:2702-13.
10.1245/s10434-007-9487-4 - 10. Mi DH, Li Z, Yang KH, et al.: Surgery combined with intraoperative hyperthermic intraperitoneal chemotherapy (IHIC) for gastric cancer: a systematic review and meta-analysis of randomised controlled trials. Int J Hyperthermia 2013;29:156-67.
- 11. Sun J, Song Y, Wang Z, et al.: Clinical significance of palliative gastrectomy on the survival of patients with incurable advanced gastric cancer: a systematic review and meta-analysis. BMC Cancer 2013;13:577. doi: 10.1186/1471-2407-13-577.:577-13.
10.1186/1471-2407-13-577.:577-13 - 12. Yan TD, Edwards G, Alderman R, et al.: Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma-a prospective study of 70 consecutive cases. Ann Surg Oncol. 2007;14:515-25.
10.1245/s10434-006-9187-5 - 13. Coccolini F, Cotte E, Glehen O, et al.: Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. Eur J Surg Oncol. 2014;40:12-26.
10.1016/j.ejso.2013.10.019 - 14. Van Der Speeten K, Stuart OA, Sugarbaker PH: Pharmacology of perioperative intraperitoneal and intravenous chemotherapy in patients with peritoneal surface malignancy. Surg Oncol Clin N Am. 22012;21:577-97.
- 15. Braam HJ, Schellens JH, Boot H, et al.: Selection of chemotherapy for hyperthermic intraperitoneal use in gastric cancer. Crit Rev Oncol Hematol. 2015;95:282-96.
- 16. Jacquet P, Sugarbaker PH: Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359-74.
- 17. Glehen O, Gilly FN, Arvieux C, et al.: Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17:2370-7.
10.1245/s10434-010-1039-7 - 18. Gill RS, Al-Adra DP, Nagendran J, et al.: Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. J Surg Oncol. 2011;104:692-8.
- 19. Rau B, Löffler M, Rau HG, et al.: Perioperative chemotherapy and cytoreductive surgery with versus without HIPEC in gastric cancer with limited peritoneal metastases: A randomized phase III study (GASTRIPEC). J Clin Oncol. 2015;33, (abstr).
- 20. Al-Batran SE, Hofheinz RD, Pauligk C, et al.: Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016;17(12):1697-708.
- 21. Costa WL, Jr., Coimbra FJ, Ribeiro HS, et al.: Safety and preliminary results of perioperative chemotherapy and hyperthermic intraperitoneal chemotherapy (HIPEC) for high-risk gastric cancer patients. World J Surg Oncol. 2012;10:195. doi: 10.1186/1477-7819-10-195.:195-10, 2012
- 22. Huang JY, Xu YY, Sun Z, et al.: Comparison different methods of intraoperative and intraperitoneal chemotherapy for patients with gastric cancer: a meta-analysis. Asian Pac J Cancer Prev. 2012;13:4379-85.
- 23. Yang XJ, Huang CQ, Suo T, et al.: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18:1575-81.
Language: English
Page range: 187 - 189
Submitted on: Sep 29, 2017
Accepted on: Dec 29, 2017
Published on: Mar 9, 2018
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
Related subjects:
© 2018 Beate Rau, Eva Pachmayr, Dusan Klos, Peter Thuss-Patience, Andreas Brandl, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.